Table 3.
Loss or reduction of 53BP1 expression correlates with triple-negative status and BRCA1/2 mutation status (Helsinki cohort)
| 53BP1 |
||||
|---|---|---|---|---|
| Features | Total (%) | Normal (%) | Aberrant (%) | p * |
| ER | 1053 | |||
| positive | 834 (79.2) | 823 (80.3) | 11 (39.3) | |
| negative | 219 (20.8) | 202 (19.7) | 17 (60.7) | 0.000004 |
| PR | 1050 | |||
| positive | 703 (67.0) | 692 (67.7) | 11 (39.3) | |
| negative | 347 (33.0) | 330 (32.3) | 17 (60.7) | 0.003 |
| ERBB2/HER2 | 1075 | |||
| positive | 145 (13.5) | 142 (13.6) | 3 (10.3) | |
| negative | 930 (86.5) | 904 (86.4) | 26 (89.7) | 0.8 |
| Triple-negative (TN) | 1018 | |||
| Not TN | 875 (86.0) | 861 (87.0) | 14 (50.0) | |
| TN | 143 (14.0) | 129 (13.0) | 14 (50.0) | 0.000004 |
| BRCA1/2 mutation | 1187 | |||
| non-BRCA1/2 | 1108 (93.4) | 1079 (94.0) | 29 (74.4) | |
| sporadic | 374 | 371 | 3 | 0.000003 † |
| familial non-BRCA1/2 | 734 | 708 | 26 | 0.001 & |
| BRCA1/2 | 79 (6.6) | 69 (6.0) | 10 (25.6) | 0.0001 ‡ |
| BRCA1 | 35 | 30 | 5 | 0.003 § |
| BRCA2 | 44 | 39 | 5 | 0.008 ¶ |
*
Fisher’s exact test
†
BRCA1/2 vs. sporadic
&
BRCA1/2 vs. familial non-BRCA1/2 tumors
‡
BRCA1/2 vs. all non-BRCA1/2 tumors (sporadic + familial non-BRCA1/2)
§
BRCA1 vs. all non-BRCA1/2 tumors
¶
BRCA2 vs. all non-BRCA1/2 tumors.